A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancersSandra Hocke(Ludwig-Maximilians-Universität München), Eike Gallmeier(Universitätsklinikum Gießen und Marburg)OncotargetJanuary 9, 201610.18632/oncotarget.6857Cited by 41SaveCiteExport RISWatch citationsRelated PapersSynthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy|Neoplasia|2024|5